GeneSoft: The Value of Compromised Products

Following the FDA's rejection of Factive, GlaxoSmithKline gave it back to its Korean owner, LG Life Sciences Now the compromised--and newly approved--product is the basis for a start-up's spectacular return from a near-death experience--and the latest in a string of biotech successes based around products the previous owners had rejected.